Open·Ingested 90 days ago, not re-verified since

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Defense Health Agency Contracting Activity - DHACA

Go to the official application

Free. Verify your email, then we send one reminder only.

Download details (file)

Posted: May 4, 2026
Amount: $12,000,000
Closes: Sep 30, 2026 (in 58 days)

Similar opportunities open now

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 58 days
DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 58 days
DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 58 days
DoW Multiple Sclerosis Clinical Trial AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 10 days
DoW Multiple Sclerosis Exploration-Hypothesis Development AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 10 days

Classification and identifiers

Solicitation number: HT942526ALSRPTDA
Assistance listing (CFDA): 12.420

Amount

$12,000,000

Who can apply

Open to all

About this opportunity

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including...